Permitted Assignment by Licensee. Subject to Section 16.3, Licensee may assign this Agreement to its successor in interest as part of a Change of Control, provided that, if Licensee is in material breach of any material provision of this Agreement, Licensee must obtain ULRF’s prior written consent to such assignment.
Appears in 2 contracts
Samples: Exclusive License Agreement (Qualigen Therapeutics, Inc.), Exclusive License Agreement (Qualigen Therapeutics, Inc.)
Permitted Assignment by Licensee. Subject to Section 16.3, Licensee may assign this Agreement (a) to its their successor in interest in connection with an investment in Licensee or as part of a Change of Control, provided that, if Licensee is then in material breach of any material provision of this AgreementAgreement and ULRF has provided written notice to Licensee of such material breach, Licensee must obtain ULRF’s prior written consent to such assignment, which ULRF shall not unreasonably withhold, condition or delay, and (b) to an Affiliate of Licensee.
Appears in 2 contracts
Samples: Exclusive License Agreement (Talaris Therapeutics, Inc.), Exclusive License Agreement (Talaris Therapeutics, Inc.)
Permitted Assignment by Licensee. Subject to Section 16.3, Licensee may assign this Agreement to its their successor in interest as part of a Change of Control, provided that, if Licensee is in material breach of any material provision of this Agreement, Licensee must obtain ULRF’s prior written consent to such assignment.
Appears in 1 contract
Samples: Exclusive License Agreement (Ritter Pharmaceuticals Inc)